Amgen announced on Tuesday the submission of a supplemental Biologics License Application to the FDA for Blincyto, or blinatumomab, to include overall survival data from the phase 3 TOWER study, supporting the conversion of Blincyto’s accelerated approval to full approval.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
